Table 4.
Reliability of tumor uptake quantification for 89Zr-immuno-PET
| Measure | 89Zr-rituximab | 89Zr-cetuximab | 89Zr-trastuzumab | |||
|---|---|---|---|---|---|---|
| D3 | D6 | D3 | D6 | D4 | ||
| SUVmax | All |
1.00; n = 26 (1.00–1.00) |
1.00; n = 32 (1.00–1.00) |
0.93; n = 7 (0.77–0.99) |
0.72; n = 10 (0.41–0.91) |
0.97; n = 28 (0.95–0.99) |
| Eligible |
1.00; n = 23 (1.00–1.00) |
1.00; n = 28 (1.00–1.00) |
NAa |
1.00; n = 8 (NA-NA) |
0.97; n = 23 (0.95–0.99) |
|
| SUVpeak | All |
1.00; n = 26 (1.00–1.00) |
1.00; n = 32 (1.00–1.00) |
0.94; n = 7 (0.82–0.99) |
0.75; n = 10 (0.46–0.92) |
0.83; n = 28 (0.69–0.92) |
| Eligible |
1.00; n = 23 (1.00–1.00) |
1.00; n = 28 (1.00–1.00) |
NAa |
1.00; n = 8 (1.00–1.00) |
0.82; n = 23 (0.64–0.91) |
|
| SUVmean | All |
0.92; n = 26 (0.84–0.96) |
0.95; n = 32 (0.91–0.97) |
0.93; n = 7 (0.79–0.99) |
0.79; n = 10 (0.56–0.96) |
0.94; n = 28 (0.89–0.97) |
| Eligible |
0.90; n = 23 (0.80–0.96) |
0.94; n = 28 (0.90–0.97) |
NAa |
0.92; n = 8 (0.73–0.98) |
0.93; n = 23 (0.86–0.97) |
|
| Volume (mL) | All |
0.85; n = 26 (0.74–0.92) |
0.12; n = 32 (−0.07–0.36) |
0.80; n = 7 (0.46–0.96) |
0.83; n = 10 (0.60–0.95) |
0.67; n = 28 (0.48–0.82) |
| Eligible |
0.87; n = 23 (0.77–0.94) |
0.72; n = 28 (0.55–0.85) |
NAa |
0.83; n = 8 (0.56–0.96) |
0.66; n = 23 (0.45–0.82) |
|
| TLU (%ID) | All |
0.90; n = 26 (0.83–0.95) |
0.65; n = 32 (0.47–0.79) |
0.86; n = 7 (0.61–0.97) |
0.89; n = 10 (0.72–0.97) |
0.71; n = 28 (0.54–0.84) |
| Eligible |
0.90; n = 23 (0.82–0.96) |
0.83; n = 28 (0.72–0.91) |
NAa |
0.89; n = 8 (0.70–0.98) |
0.70; n = 23 (0.51–0.85) |
|
Data presented as ICC (95% confidence interval)
aNA ICC not available, 2 eligible VOI